

# Driving Visionary Expansion via Hong Kong

**Eyebright Medical sets its sights on global expansion from its Hong Kong base of operations.**

Hong Kong's unique position as a global hub for innovation and talent has made it the ideal international headquarters for Mainland Chinese ophthalmic medical device manufacturer Eyebright Medical Technology (Beijing) Co., Ltd (Eyebright Medical). With strong government support and a dynamic innovation and technology (I&T) ecosystem, the company is poised to bring its innovative eye care solutions to the world stage through Hong Kong.

Eyebright Medical is a pioneer in intraocular lenses and specialises in the ophthalmic fields of cataract surgery, myopia management and consumer vision care. Its main products include intraocular lenses (to treat cataracts), orthokeratology lenses (to reshape the cornea for vision improvement) and soft contact lenses. Over the past 15 years since its establishment by Dr Xie Jiangbing, Eyebright Medical's products have expanded to cover the entire life cycle of eye health.

The company has been continuously launching innovative products, including its self-developed, China's first aspheric phakic intraocular lens, the Loong Crystal™ PR. The product received a Class III Medical Devices Certificate from the National Medical Products Administration in early January 2025, making the company one of the few globally with approved commercialisation of phakic intraocular lens products. It is expected to challenge the long-standing dominance of the implantable collamer lens (ICL) products in the Chinese and global markets.

## Ideal Gateway for Global Expansion

Eyebright Medical's Hong Kong office was set up in 2023, serving as its international headquarters. Xie believes that the city is the perfect place to realise his vision of introducing Chinese-made intraocular lenses to the world. "As a global hub, Hong Kong is a gateway to international markets with established trade agreements

**“ The Hong Kong government's initiatives such as the Innovation and Technology Fund supports R&D, complemented by policies designed to foster a thriving startup ecosystem, which is vital for driving economic and technological growth. ”**

**Dr Xie Jiangbing  
Chairman  
Eyebright Medical**

and policies that facilitate cross-border transactions,” he said. “This access to global markets allows us to expand our reach and enhance growth opportunities. We are currently in discussions with several research and development (R&D) projects with renowned Hong Kong universities, and we expect to establish long-term partnerships with the institutions to create more synergy in the future.”

## Government Support for I&T Advancement

“The Hong Kong government's initiatives, such as the Innovation and Technology Fund, support R&D,” noted Xie. “These efforts are complemented by policies designed to foster a thriving startup ecosystem, which is vital for driving economic and technological growth. Additionally, InvestHK's tailored support helps us navigate the local market and showcase our innovations globally.”

Xie sees Hong Kong's deep talent pool as a great resource for staffing Eyebright. “The city has a highly skilled workforce with a strong emphasis on education and



professional development, particularly in the fields of medicine, life sciences and healthcare management,” he stated. “The city's rich cultural diversity plays a crucial role in driving innovation in the healthcare sector.”

## Eyebright Medical

- Established in Beijing in 2010, the company is listed on the Shanghai Stock Exchange
- The company has branches in Yantai, Suzhou, Hangzhou, Lianyungang, Chengdu, Fuzhou, Hong Kong, Switzerland and other locations
- Hong Kong office was set up in 2023, focusing on business development, talent acquisition, financing and R&D activities

 [ebmedical.com/en](http://ebmedical.com/en)